ELISA/assay

KRIBIOLISA™ Obrindatamab ELISA

KBI1763

1 x 96 wells

1050 USD

KRIBIOLISA™ Obrindatamab ELISA

ELISA

1 x 96 wells

1050 USD

ELISA for the detection of Obrindatamab in human serum and plasma. Lead time for this kit is 5 weeks. About the kit: - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life: 1 year.Obrindatamab is an activating bispecific molecule that binds to both B7-H3 (CD276) and CD3, therefore bringing the targeted B7-H3-expressing cells together with T-cells, resulting in cytotoxic immune response. Upon administration of the drug, the anti-B7-H3 component targets and binds to the cell surface antigen B7-H3; at the same time, the anti-CD3 component binds to human CD3. This cross-links the T cells to B7-H3-expressing tumor cells, activates and redirects endogenous T cells to kill B7-H3-expressing tumor cells, and inhibits proliferation of B7-H3-expressing tumor cells.

Human

This ELISA kit comes with a pre-coated plate, concentrated or lyophilized standards, wash solution, subtrate, stop solution and all the required diluents. For the exact contents of the kit, please refer to the datasheet / IFU.

2-8 Deg C

0 ug/ml - 100 ug/ml

7.5 ug/ml

This ELISA employs the quantitative sandwich enzyme immunoassay technique to detect and capture the target bispecific antibody. One target protein to which the bsAb binds is pre-coated onto microwells. Samples and standards are pipetted into microwells and the target bsAb drug present in the sample are bound by the capture antibody. Then, the second target protein to which the bsAb binds wtih HRP (horseradish peroxidase) conjugation is then pipetted and wells are incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of bsAb drug in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Obrindatamab

RUO

2-8 degrees C